Treatment
List of documents by year
2017
- Status report on artemisinin and ACT resistance (April 2017)
- WHO preferred product characteristics: endectocide for malaria transmission control
2016
- Global Fund – funding proposal development – WHO policy brief 2016
- Status report on artemisinin and ACT resistance (April 2016)
- Status report on artemisinin and ACT resistance (October 2016)
- Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale
- WHO malaria terminology
2015
- Control and elimination of Plasmodium vivax malaria – A technical brief
- Global Technical Strategy for Malaria 2016–2030
- Guidelines for the treatment of malaria. Third edition
- Policy brief on single-dose primaquine as a gametocytocide in Plasmodium falciparum malaria
- Recommendations on intermittent screening and treatment in pregnancy and the safety of ACTs in the first trimester
- Recommendations on the role of mass drug administration, mass screening and treatment, and focal screening and treatment for malaria
- Status report on artemisinin and ACT resistance (September 2015)
2014
- Guidance on temporary malaria control measures in Ebola-affected countries
- Safety of 8-aminoquinoline antimalarial medicines
- Severe malaria
- Status report on artemisinin resistance (January 2014)
- Status report on artemisinin resistance (September 2014)
- WHO policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP)
2013
- Information note on delayed haemolytic anaemia following treatment with artesunate
- Management of severe malaria – A practical handbook. Third edition
- Seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in children: A field guide
- Universal access to malaria diagnostic testing – An operational manual
- WHO informal consultation on fever management in peripheral health care settings: A global review of evidence and practice
2012
- T3: Test. Treat. Track. Scaling up diagnostic testing, treatment and surveillance for malaria
- Update on artemisinin resistance ‐ April 2012
- Updated WHO policy recommendation: intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP)
- Updated WHO policy recommendation: Single dose primaquine as a gametocytocide in Plasmodium falciparum malaria
- WHO policy recommendation: Seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa
- WHO position statement: Effectiveness of non-pharmaceutical forms of Artemisia annua L. against malaria
2011
- Intermittent preventive treatment for infants using sulfadoxine-pyrimethamine (IPTi-SP) for malaria control in Africa: implementation field guide
- Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies
- Update on artemisinin resistance ‐ September 2011
2010
- Good procurement practices for artemisinin-based antimalarial medicines
- WHO Policy recommendation on intermittent preventive treatment during infancy with sulphadoxine-pyrimethamine (IPTi-SP) for Plasmodium falciparum malaria control in Africa
2009 and earlier
- A practical handbook on the pharmacovigilance of antimalarial medicines
- Malaria case management: operations manual
- Methods and techniques for clinical trials on antimalarial drug efficacy: Genotyping to identify parasite populations
- Methods for surveillance of antimalarial drug efficacy
- Review of the safety of chlorproguanil–dapsone the treatment uncomplicated falciparum malaria in Africa
- Specifications for prepackaging antimalarial medicines. Technical consultation report
- WHO informal consultation with manufacturers of artemisinin-based pharmaceutical products in use for the treatment of malaria
Archived publications
- Access to antimalarial medicine: improving the affordability and financing of artemisinin-based combination therapies (archived)
- Antimalarial drug combination therapy (archived)
- Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria (archived)
- Assessment of the safety of artemisinin compounds in pregnancy (archived)
- Clinical, behavioural and socioeconomic factors related to severe malaria. A Multicenter Study in the Africa Region (archived)
- Community involvement in Rolling Back Malaria (archived)
- Consideration of mass drug administration for the containment of artemisinin-resistant malaria in the Greater Mekong subregion (archived)
- Emergence and spread of artemisinin resistance calls for intensified efforts to withdraw oral artemisinin-based monotherapy from the market (archived)
- Improving access to antimalarial medicines. Report of the RBM Partnership meeting, 30 September–2 October 2002 (archived)
- Malaria rapid diagnosis - Making it work. Meeting report (archived)
- Meeting on the production of artemisinin and artemisinin-based combination therapies (archived)
- Position of WHO's Roll Back Malaria Department on malaria treatment policy (archived)
- Scaling up home-based management of malaria. From research to implementation (archived)
- Susceptibility of plasmodium falciparum to antimalarial drugs. Report on global monitoring 1996-2004 (archived)
- Technical Expert Group meeting on intermittent preventive treatment in pregnancy - IPTp (archived)
- The Roll Back Malaria strategy for improving access to treatment through home management of malaria (archived)
- The use of antimalarial drugs. Consultation report (archived)
- The use of artemisinin and its derivatives as anti-malarial drugs. Consultation report (archived)
- The use of malaria rapid diagnostic tests (archived)
- Towards quality testing of malaria rapid diagnostic tests: evidence and methods (archived)
- Use of rectal artemisinin-based suppositories in the management of severe malaria. Meeting report (archived)